JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer
This is an open-label phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics and initial efficacy of JS004 injection combined with toripalimab and with or without standard chemotherapy in patients with advanced lung cancer
Advanced Lung Cancer
BIOLOGICAL: Recombinant humanized anti-BTLA monoclonal antibody (JS004) injection|BIOLOGICAL: Toripalimab|DRUG: Docetaxel|DRUG: Pemetrexed|DRUG: Cisplatin|DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: Etoposide
Incidence of adverse events (AEs), Incidence of adverse events (AEs), 2 years|Incidence of SAEs, Incidence of serious adverse events (SAEs), 2 years|Incidence of irAEs, Incidence of immune-related adverse events (irAEs), 2 years|ORR, Efficacy endpoint: objective response rate (ORR) based on RECIST v1.1 criteria, 2 years
DOR, Efficacy endpoints: duration of response, 2 years|DCR, Efficacy endpoints: disease control rate, 2 years|time to response (TTR), Efficacy endpoints: time to response, 2 years|PFS, Efficacy endpoints: progression-free survival, 2 years|OS, Efficacy endpoints: overall survival (OS), 2 years|1-year OS rate, Efficacy endpoints: 1-Year overall survival (OS) rate, 1 year|Drug concentration in plasma, drug concentration at different time points after administration in an individual subject, 2 years|incidence of ADA, incidence of anti-drug antibodies (ADA), 2 years|titer of ADA, titer of anti-drug antibodies (ADA), 2 years|incidence of Nab, incidence of neutralizing antibodies (Nab), 2 years|titer of Nab, titer of neutralizing antibodies (Nab), 2 years
This is an open-label phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics and initial efficacy of JS004 injection combined with toripalimab and with or without standard chemotherapy in patients with advanced lung cancer